• National Institute of Drug Clinical Trial/GCP Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P. R. China;
QINYong-ping, Email: qinyping1@163.com
Export PDF Favorites Scan Get Citation

Objective To study the pharmacokinetics of lovastatin/niacin sustained-release tablets in healthy Chinese volunteers. Methods Eligible subjects were enrolled to receive a single dose of 20/500, 20/750 and 20/1 000 mg lovastatin/niacin sustained-release tablets and multiple dose of 20/1 000 mg lovastatin/niacin sustainedrelease tablets, one time per day, sustained for 5 days, respectively. Blood samples were obtained before dosing and up to 10, 20, 30, and 45 minutes, and 1 hour, 1.5, 2, 2.5, 3, 3.5, 4, 5, 7, 9, 12, and 15 hours after dosing. Niacin, niacinamide, nicotinuric acid and lovastatin were detected by high performance liquid chromatography-tandem mass spectrometry method. Results The peak concertration and the area under the plasma concentration-time curve (0-t) of nicotinuric acid had linear dynamics characteristics with the dosage when the dose of niacin was between 500 and 1 000 mg. After multiple dosing, pharmacokinetics parameters of nicotinuric acid and lovastatin were close. No significant diTherence was found between male and female subjects. Conclusion Lovastatin/niacin sustained-release tablets possess linear kinetics. Accumulation is not significant after multiple dosing. Gender doesn't affect the pharmacokinetics parameters.

Citation: LUOZhu, LIANGMao-zhi, WANGYing, YUQin, SHENQi, QINYong-ping. Pharmacokinetic Study of Lovastatin/niacin Sustained-release Tablets in Healthy Chinese Volunteers. West China Medical Journal, 2015, 30(10): 1881-1886. doi: 10.7507/1002-0179.20150540 Copy

Copyright © the editorial department of West China Medical Journal of West China Medical Publisher. All rights reserved

  • Previous Article

    A Randomized Controlled Trial on Holmium Laser Resection and Plasmakinetic Resection of Bladder Tumors
  • Next Article

    Pharmaceutical Care for One Patient with Breast Cancer Complicated with Multiple Metastases by Clinical Pharmacists